Allergy and Immunology · Ventura, CA
NPI
1972787638
Since 2007
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
5720 Ralston St, Suite 205
Ventura, CA, 93003
Phone (805) 658-9500
Groups this clinician bills Medicare through
Medicare paid, 2024
$734K
37,611 services
Medicare patients, 2024
221
Average age 73
Drug cost, 2024
$554K
659 prescriptions
Company payments, 2025
$12K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Prashant Verma was code 95004 (test - miscellaneous), 4,241 times for 49 patients. In total Prashant Verma billed 37,611 services in 41 codes, and Medicare paid $734K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 4,241 | 49 | $2.90 | $12K |
| 95165 Treatment - Miscellaneous | Office | 2,466 | 46 | $12.77 | $31K |
| 95024 Test - Miscellaneous | Office | 756 | 27 | $7.20 | $5,443 |
| 95117 Treatment - Miscellaneous | Office | 675 | 38 | $10.36 | $6,990 |
| 96160 E&M - Miscellaneous | Office | 181 | 80 | $2.49 | $451 |
| 96372 Injection Administration | Office | 156 | 22 | $12.39 | $1,933 |
| 99214 Office E&M - Established | Office | 152 | 90 | $99.73 | $15K |
| 99213 Office E&M - Established | Office | 95 | 67 | $66.19 | $6,288 |
| 99204 Office E&M - New | Office | 59 | 59 | $132.87 | $7,839 |
| 96365 Intravenous Infusion, Hydration | Office | 46 | 13 | $56.32 | $2,590 |
| 95012 Pulmonary | Office | 21 | 21 | $13.24 | $278 |
| 99211 Office E&M - Established | Office | 13 | 12 | $15.97 | $208 |
By year: 2022 $99K for 9,679 services; 2023 $519K for 31,985 services; 2024 $734K for 37,611 services.
Medicare prescription drug claims, 2024
In 2024, the drug Prashant Verma prescribed most often to Medicare patients was Ipratropium Bromide, with 71 prescriptions and refills. In total Prashant Verma wrote 659 Medicare prescriptions that cost $554K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ipratropium Bromide Generic | 71 | 130 | 37 | $1,951 |
| Montelukast Sodium Generic | 47 | 115 | 22 | $492 |
| Azelastine Hcl Generic | 43 | 73 | 19 | $1,543 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 39 | 55 | Under 11 | $34K |
| Fluticasone Propionate Generic | 35 | 57 | 17 | $445 |
| Nucala Mepolizumab | 29 | 29 | Under 11 | $105K |
| Famotidine Generic | 26 | 34 | Under 11 | $198 |
| Breo Ellipta Fluticasone/Vilanterol | 24 | 28 | Under 11 | $11K |
| Triamcinolone Acetonide Generic | 23 | 25 | 19 | $124 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 23 | 23 | Under 11 | $1,463 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 21 | 31 | 17 | $705 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 19 | 23 | Under 11 | $1,963 |
| Arnuity Ellipta Fluticasone Furoate | 19 | 27 | Under 11 | $5,886 |
| Prednisone Generic | 15 | 15 | 13 | $20.68 |
| Advair Hfa Fluticasone Propion/Salmeterol | 15 | 16 | Under 11 | $4,418 |
Brand drugs: - claims; generic drugs: 398 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Prashant Verma $12K ($12K in general payments such as food, travel and fees) from 25 companies. The largest payer was CSL Behring with $8,083.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 7 | $8,083 |
| AstraZeneca Pharmaceuticals LP AZN | 23 | $1,136 |
| Amgen Inc. AMGN | 18 | $632 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $525 |
| Genzyme Corporation SNY | 13 | $437 |
| GlaxoSmithKline, LLC. GSK | 20 | $345 |
| ALK-Abello, Inc | 1 | $153 |
| Incyte Corporation INCY | 4 | $109 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 4 | $106 |
| Greer Laboratories, Inc. | 1 | $95.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.